Modern Approaches to Cancer Treatment
Lecture Notes in Computer Science (including subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics), ISSN: 1611-3349, Vol: 13346 LNBI, Page: 216-226
2022
- 1Citations
- 2Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Conference Paper Description
Cancer remains the most common worldwide problem with the highest impact on global health. It is the second leading cause of death, due to the lack of early diagnosis and high recurrence rate after conventional therapies. Although every year several new therapeutic approaches are proposed the urgent need for more effective therapeutic strategies to improve the survival rate and life expectancy of cancer patients rapidly grows. A recent promising anticancer strategy is based on multinuclear heterocycles as widely investigated bioactive molecules, considered important synthetic targets for the development of novel therapeutic agents. Many nitrogen heterocycles are known for a long time as natural alkaloids, known to possess the broad and diverse biological activity and medicinal applicability. Nowadays however novel multinuclear drug-like heterocyclic structures are generated by methods of artificial intelligence. Novel approaches are required as more expeditious ways of studying their biological activity, capable of more than explaining their activity, and even prognosticating it. This study highlights our and other authors’ recent results on the biological activity of multinuclear heterocyclic molecules on cancer cells, explicitly based on their capacity to bind to G-quadruplexes. It further stresses the need for novel G-quadruplex binding compounds, with elucidated biochemical mechanisms of action for biomedical applications, namely in anticancer therapies.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85132972769&origin=inward; http://dx.doi.org/10.1007/978-3-031-07704-3_18; https://link.springer.com/10.1007/978-3-031-07704-3_18; https://dx.doi.org/10.1007/978-3-031-07704-3_18; https://link.springer.com/chapter/10.1007/978-3-031-07704-3_18
Springer Science and Business Media LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know